|
| Aurintricarboxylic acid |
|
Yersinia |
TTSS secreted effectors |
Preclinical (in vivo) |
Liang F, et al. 2003. J Biol Chem |
|
| 4,4'-bis-(3-Carboxy-4-chloroanilino)tritylium chloride |
|
Yersinia |
TTSS secreted effectors |
Preclinical (in vivo) |
Liang F, et al. 2003. J Biol Chem |
|
| 6-[(4-nitrobenzoyl)amino]hexanoic Acid |
|
Yersinia |
TTSS secreted effectors |
Preclinical (in vivo) |
Liang F, et al. 2003. J Biol Chem |
|
| 9-Fluorenone-1-carboxylic acid |
|
Yersinia |
TTSS secreted effectors |
Preclinical (in vivo) |
Liang F, et al. 2003. J Biol Chem |
|
| 1-Pyrenecarboxylic acid |
|
Yersinia |
TTSS secreted effectors |
Preclinical (in vivo) |
Liang F, et al. 2003. J Biol Chem |
|
| Chrome Azurol S |
|
Yersinia |
TTSS secreted effectors |
Preclinical (in vivo) |
Liang F, et al. 2003. J Biol Chem |
|
Compound 2
(internal name in literature) |
|
Bacillus |
Collagenase |
Preclinical (in vivo) |
Alhayek A, et al. 2022. Adv Ther (Weinh) |
|
| 2-hydroxy-N-[(Z)-1-(4-phenylphenyl)ethylideneamino]benzamide |
|
Brucella |
VirB type IV secretion system |
Preclinical (in vivo) |
Paschos A, et al. 2011. Infect Immun |
|
| 2-hydroxy-N-[(Z)-[5-(2-nitrophenyl)furan-2-yl]methylideneamino]benzamide |
|
Brucella |
VirB type IV secretion system |
Preclinical (in vivo) |
Paschos A, et al. 2011. Infect Immun; Smith MA, et al. 2012. Chem Biol |
|
| 2-[3-[(5E)-5-[3-[3-(2-carboxyanilino)-3-oxopropyl]-4-oxo-2-sulfanylidene-1,3-thiazolidin-5-ylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]propanoylamino]benzoic acid |
|
Brucella |
VirB type IV secretion system |
Preclinical (in vivo) |
Paschos A, et al. 2011. Infect Immun |
|
| | | |
